HRS Guidelines Bundle (free trial)

Evaluation and Management of Arrhythmic Risk in Neuromuscular Disorders

Heart Rhythm Society GUIDELINES Apps brought to you free pf charge, courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1499527

Contents of this Issue

Navigation

Page 3 of 49

4 Table 1. Genetics, cardiovascular complications, and NMDs NMD Section Heritance Gene locus Disease protein DMD 3 X-linked (XL) Xp21 Dystrophin BMD 3 XL Xp21 Dystrophin Limb-girdle muscular dystrophy type 2 (LGMD2) a 3 Autosomal recessive (AR) Various Various DM1 4 Autosomal dominant (AD) 19q13 Myotonic dystrophy protein kinase (DMPK) DM2 4 AD 3q21 Zinc finger 9 (ZNF9) EDMD 5 XL Xq28 Emerin LGMD1B a 5 AD 1q11-21 Lamin A/C Facioscapulohumeral muscular dystrophy (FSHD) 6 AD 4q D4Z4 Double homeobox 4 (DUX4) Friedreich ataxia (FA) 7 AR 9q21.11 Frataxin Kearns-Sayre syndrome 7 AD Mitochondrial DNA (mtDNA) Various e table includes the section of the document that covers the specific NMD. e relative frequencies of the type of cardiac manifestation are included. e type of CM is dilated unless otherwise indicated. a A reclassification and revised nomenclature for LGMD has been suggested by the 229th European Neuromuscular Centre workshop, with recessive LGMD2 renamed LGMD R1–R24 (see Table 2) in addition to descriptive names for some of the recessive variants and LMNA-associated myopathies (LGMD1B, Emery-Dreifuss muscular dystrophy types 2 and 3 [EDMD2, EDMD3]) named EDMD. Straub V, Murphy A, Udd B, et al. Neuromuscul Disord 2018;28:702–710. General Principles for Arrhythmic Risk in NMDs

Articles in this issue

Archives of this issue

view archives of HRS Guidelines Bundle (free trial) - Evaluation and Management of Arrhythmic Risk in Neuromuscular Disorders